These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

582 related items for PubMed ID: 16875644

  • 1. Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study.
    Langer RD, Landgren BM, Rymer J, Helmond FA, OPAL Investigators.
    Am J Obstet Gynecol; 2006 Nov; 195(5):1320-7. PubMed ID: 16875644
    [Abstract] [Full Text] [Related]

  • 2. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study.
    Bots ML, Evans GW, Riley W, McBride KH, Paskett ED, Helmond FA, Grobbee DE, OPAL Investigators.
    Eur Heart J; 2006 Mar; 27(6):746-55. PubMed ID: 16415304
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Endometrial effects of tibolone.
    Archer DF, Hendrix S, Gallagher JC, Rymer J, Skouby S, Ferenczy A, den Hollander W, Stathopoulos V, Helmond FA.
    J Clin Endocrinol Metab; 2007 Mar; 92(3):911-8. PubMed ID: 17192288
    [Abstract] [Full Text] [Related]

  • 5. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy.
    Simon JA, Liu JH, Speroff L, Shumel BS, Symons JP.
    Am J Obstet Gynecol; 2003 Jan; 188(1):92-9. PubMed ID: 12548201
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability.
    Baracat EC, Barbosa IC, Giordano MG, Haidar MA, Marinho RM, Menegocci JC, Morais KM, Tomaz G, Wehba S.
    Climacteric; 2002 Mar; 5(1):60-9. PubMed ID: 11974560
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study: design and baseline characteristics.
    Bots ML, Evans GW, Riley W, Meijer R, McBride KH, Paskett ED, Helmond FA, Grobbee DE, OPAL Investigators.
    Control Clin Trials; 2003 Dec; 24(6):752-75. PubMed ID: 14662281
    [Abstract] [Full Text] [Related]

  • 11. Effect on sexual life--a comparison between tibolone and continuous combined conjugated equine estrogens and medroxyprogesterone acetate.
    Uygur D, Yeşildaglar N, Erkaya S.
    Gynecol Endocrinol; 2005 Apr; 20(4):209-12. PubMed ID: 16019363
    [Abstract] [Full Text] [Related]

  • 12. Long-term effects of tibolone on the endometrium as assessed by bleeding episodes, transvaginal scan and endometrial biopsy.
    Bruce D, Robinson J, Rymer J.
    Climacteric; 2004 Sep; 7(3):261-6. PubMed ID: 15669550
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A prospective 1-year study of estrogen and progestin in postmenopausal women: effects on the endometrium.
    Gelfand MM, Ferenczy A.
    Obstet Gynecol; 1989 Sep; 74(3 Pt 1):398-402. PubMed ID: 2548135
    [Abstract] [Full Text] [Related]

  • 16. Bleeding pattern and endometrial changes during continuous combined hormone replacement therapy. The Ogen/Provera Study Group.
    Nand SL, Webster MA, Baber R, O'Connor V.
    Obstet Gynecol; 1998 May; 91(5 Pt 1):678-84. PubMed ID: 9572210
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women.
    Huber J, Palacios S, Berglund L, Hänggi W, Sathanandan SM, Christau S, Helmond F.
    BJOG; 2002 Aug; 109(8):886-93. PubMed ID: 12197367
    [Abstract] [Full Text] [Related]

  • 19. Effects of two different regimens of continuous hormone replacement therapy on endometrial histopathology and postmenopausal uterine bleeding.
    Yildirim G, Tugrul S, Uslu H, Pekin O, Eren S.
    Arch Gynecol Obstet; 2006 Feb; 273(5):268-73. PubMed ID: 16315025
    [Abstract] [Full Text] [Related]

  • 20. Short-term and long-term effects of tibolone in postmenopausal women.
    Formoso G, Perrone E, Maltoni S, Balduzzi S, Wilkinson J, Basevi V, Marata AM, Magrini N, D'Amico R, Bassi C, Maestri E.
    Cochrane Database Syst Rev; 2016 Oct 12; 10(10):CD008536. PubMed ID: 27733017
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.